TrialBritish journal of cancer2017

A Phase 1 study of ARQ 087, an oral pan-FGFR inhibitor in patients with advanced solid tumours.

K P Papadopoulos et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.